Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Hongkang Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Florey, The University of Melbourne, Parkville, Victoria 3052, Australia. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Receptors, Peptide, Insulin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: State Government of Victoria, National Health and Medical Research Council.
Abstract (Originalsprache)
Human insulin-like peptide 5 (INSL5) is a gut hormone produced by colonic L-cells, and its biological functions are mediated by Relaxin Family Peptide Receptor 4 (RXFP4). Our preliminary data indicated that RXFP4 agonists are potential drug leads for the treatment of constipation. More recently, we designed and developed a novel RXFP4 antagonist, A13-nR that was shown to block agonist-induced activity in cells and animal models. We showed that A13-nR was able to block agonist-induced increases in colon motility in mice of both genders that express the receptor, RXFP4. Our data also showed that colorectal propulsion induced by intracolonic administration of short-chain fatty acids was antagonized by A13-nR. Therefore, A13-nR is an important research tool and potential drug lead for the treatment of colon motility disorders, such as bacterial diarrhea. However, A13-nR acted as a partial agonist at high concentrations in vitro and demonstrated modest antagonist potency (∼35 nM). Consequently, the primary objective of this study is to pinpoint novel modifications to A13-nR that eliminate partial agonist effects while preserving or augmenting antagonist potency. In this work, we detail the creation of a series of A13-nR-modified analogues, among which analogues 3, 4, and 6 demonstrated significantly improved RXFP4 affinity (∼3 nM) with reduced partial agonist activity, enhanced antagonist potency (∼10 nM) and maximum agonist inhibition (∼80 %) when compared with A13-nR. These compounds have potential as candidates for further preclinical evaluations, marking a significant stride toward innovative therapeutics for colon motility disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Florey, The University of Melbourne, Parkville, Victoria 3052, Australia.
- Faculty of Pharmacy and Pharmaceutical Sciences, Monash Institute of Pharmaceutical Sciences, Victoria 3052, Australia.
- The Florey, The University of Melbourne, Parkville, Victoria 3052, Australia; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3052, Australia.
- The Florey, The University of Melbourne, Parkville, Victoria 3052, Australia; School of Chemistry, The University of Melbourne, Parkville, Victoria 3052, Australia. Electronic address: akhter.hossain@unimelb.edu.au.
Förderung
- State Government of Victoria
- National Health and Medical Research Council
Zitieren
APA
Wu, H., Handley, T. N. G., Hoare, B. L., Hartono, H. A., Scott, D. J., Chalmers, D. K., Bathgate, R. A. D., & Hossain, M. A. (2024). Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116239
Vancouver
Wu H, Handley TNG, Hoare BL, Hartono HA, Scott DJ, Chalmers DK, et al. Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116239
BibTeX
@article{Wu2024,
author = {Wu, Hongkang and Handley, Thomas N G and Hoare, Bradley L and Hartono, Herodion A and Scott, Daniel J and Chalmers, David K and Bathgate, Ross A D and Hossain, Mohammed Akhter},
title = {Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116239}
}
EUVIMED